Implanet Stock

Implanet Gross Margin

The Gross Margin of Implanet (ALIMP.PA) as of Aug 7, 2026 is 53.05 %. In the previous year, Gross Margin was 56.83 % — a change of -6.65% (lower).

Gross Margin

53.05 %

YoY

-6.65%

Last updated:

Gross Margin of Implanet is 2026 53.05 % . Gross Margin of Implanet was 2025 56.83 % . It decreases by -6.65% lower compared to the previous year.

Implanet's gross margin stands at 53.1%, down from 65.6% several years earlier.

Access this data via the Eulerpool API

Implanet Stock analysis

What does Implanet do? Implanet SA is a French company that specializes in the manufacture and distribution of innovative medical products. The company was founded in 2007 by Ludovic Lastennet and Rémi Boyer and is headquartered in Bordeaux, France. Implanet's business model focuses on the development, production, and marketing of medical implants and instruments to support orthopedic surgeries. The company works closely with leading surgeons and healthcare facilities to find the ideal solution for patient needs. One of Implanet's main areas of expertise is the spine. The company develops various implantable products for the treatment of degenerative diseases such as scoliosis. Another important area for Implanet is orthopedics, where the company develops solutions for joint problems like knee or hip replacements. The company also creates customized implants tailored to each individual patient for maximum accuracy and effectiveness. A key aspect of Implanet's business model is adapting its products to meet customer requirements. The company collaborates closely with its customers to meet their specific needs and deliver the best possible solution. Implanet is committed to developing innovative solutions that align with surgeons' capabilities and cater to their needs. Implanet maintains partnerships and distribution agreements worldwide to sell its products and achieve market gains. The company distributes its products in the US, Europe, and Asia. To further expand its presence in these markets, Implanet collaborates closely with healthcare organizations and surgeons to ensure its products remain up-to-date and meet customer needs. Implanet strives to develop innovative solutions that revolutionize orthopedics and spine care. The company has already achieved significant success in the past with its Jazz technology, which serves as an excellent example of how the company operates in a customer-oriented and innovative manner. The Jazz technology is an implant designed for scoliosis treatment and is customized to each individual patient. Overall, Implanet has developed an innovative and customer-oriented business model that focuses on continuous product development and collaboration with surgeons and healthcare organizations. With a strong presence in the global market and a range of innovative products, the company positions itself as one of the leading providers in the field of spine care and orthopedics. Implanet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Implanet stock

Gross Margin of Implanet is 53.05 % in 2026.

Gross Margin of Implanet changed from 56.83 % to 53.05 %, representing a -6.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Implanet since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Implanet with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Implanet

All Key Metrics — Implanet